ImmunityBio Treats First Patients in Europe With Anktiva Plus BCG
ImmunityBio said the first patients in Europe received Anktiva in combination with Bacillus Calmette-Guérin (BCG).
ImmunityBio (IBRX) clocked a major milestone in its European expansion on Wednesday, after the biotech firm said the first patients in Europe received its bladder cancer treatment, Anktiva, in combination with Bacillus Calmette-Guérin (BCG).Shares of IBRX traded 1% higher at the time of writing.Fir…